Brief: Windtree Acquires Early-Stage, Novel Oncology Platform, Completes $1.5 Mln Convertible Note Bridge Financing
08/04/2024 22:06
April 8 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE ACQUIRES EARLY-STAGE, NOVEL ONCOLOGY PLATFORM AND
COMPLETES $1.5 MILLION CONVERTIBLE NOTE BRIDGE FINANCING
Source text for Eikon: ID:nGNX4vdhKM
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study